All In Biotech

Drug Trial Radar · NCT05327803

Study of Epetraborole in Patients With Treatment-refractory MAC Lung Disease

A Phase 2/3, Randomized, Double-blind, Placebo-controlled, Multicenter, Prospective Study to Assess the Efficacy, Safety, and Pharmacokinetics of Orally Administered Epetraborole in Patients With Treatment-refractory Mycobacterium Avium Complex Lung Disease

Last checked: Nov 19, 2026Latest source record: Jun 10, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

TerminatedResults posted on the registryPivotal-lookingPhase 3. Randomized with 177 participants. This is a heuristic, not a regulatory label.

Status

Terminated

Enrollment

177

Actual

Start

May 20, 2022

Primary completion

Dec 18, 2024

Study completion Dec 18, 2024

Sponsor

Lead sponsor
AN2 Therapeutics, IncIndustry
Sponsor type
Industry
First posted
Apr 14, 2022

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2 / Phase 3
Allocation
Randomized
Model
Parallel
Masking
Triple (participant, care provider, investigator)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a pivotal Phase 2/3, double-blind, placebo-controlled study of epetraborole + OBR (Optimized Background Regimen) versus placebo + OBR in patients with treatment-refractory MAC lung disease. This study will enroll adult patients with treatment-refractory MAC lung disease who meet all eligibility criteria (including clinical, radiographic, and microbiological criteria).

Conditions

  • MAC Lung Disease
  • Treatment Refractory MAC Lung Disease

Interventions

  • EpetraboroleDrug

    500 mg taken orally QD

  • PlaceboDrug

    Placebo taken orally QD

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Phase 2: Adverse Event Profile of 500 mg Once Daily Dose of EpetraboroleTime frame: Baseline to Month 16
  2. Phase 2: Percentage of Participants Achieving Clinical ResponseTime frame: Baseline to Month 6
  3. Phase 3: Percentage of Participants Achieving Clinical ResponseTime frame: Baseline to Month 6

Locations

91 sites in 4 countries. Site status is shown where the registry gives one.

  • 423032

    Birmingham, Alabama

  • 423037

    Tucson, Arizona

  • 423070

    Sacramento, California

  • 423069

    San Francisco, California

  • 423006

    Stanford, California

  • 423068

    Washington D.C., District of Columbia

  • 423075

    Bay Pines, Florida

  • 423018

    DeLand, Florida

  • 423034

    Kissimmee, Florida

  • 423033

    Tampa, Florida

  • 423054

    Tampa, Florida

  • 423047

    Tampa, Florida

  • 423038

    Vero Beach, Florida

  • 423027

    Atlanta, Georgia

  • 423076

    Indianapolis, Indiana

  • 423029

    Iowa City, Iowa

  • 423015

    Kansas City, Kansas

  • 423063

    Wichita, Kansas

  • 423065

    Jefferson, Louisiana

  • 423042

    New Orleans, Louisiana

  • 423060

    Baltimore, Maryland

  • 423003

    Baltimore, Maryland

  • 423074

    Boston, Massachusetts

  • 423061

    Boston, Massachusetts

  • 423078

    Ann Arbor, Michigan

  • 423031

    Rochester, Minnesota

  • 423008

    St Louis, Missouri

  • 423004

    Omaha, Nebraska

  • 423009

    Lebanon, New Hampshire

  • 423024

    Manhasset, New York

  • 423014

    New York, New York

  • 423013

    New York, New York

  • 423071

    Chapel Hill, North Carolina

  • 423072

    Charlotte, North Carolina

  • 423017

    Durham, North Carolina

  • 423039

    Winston-Salem, North Carolina

  • 423079

    Cleveland, Ohio

  • 423082

    Oklahoma City, Oklahoma

  • 423007

    Portland, Oregon

  • 423002

    Philadelphia, Pennsylvania

Showing 40 of 91 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.